---
title: "Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289913379.md"
description: "On June 16, 2026, Cognition Therapeutics, Inc., a company listed on NASDAQ under the ticker symbol CGTX, specializing in developing drugs for neurodegenerative conditions, shared the reception of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) pertaining to patent application 19/563,468. This marks a significant milestone for the clinical-stage company in its mission to advance treatments for such disorders."
datetime: "2026-06-16T11:32:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289913379.md)
  - [en](https://longbridge.com/en/news/289913379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289913379.md)
generator: "portal-rs"
---

# Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

On June 16, 2026, Cognition Therapeutics, Inc., a company listed on NASDAQ under the ticker symbol CGTX, specializing in developing drugs for neurodegenerative conditions, shared the reception of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) pertaining to patent application 19/563,468. This marks a significant milestone for the clinical-stage company in its mission to advance treatments for such disorders.

### Related Stocks

- [CGTX.US](https://longbridge.com/en/quote/CGTX.US.md)

## Related News & Research

- [Cognition Therapeutics Q2 net loss narrows on lower R&D costs](https://longbridge.com/en/news/295139858.md)
- [Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website](https://longbridge.com/en/news/292481427.md)
- [Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis](https://longbridge.com/en/news/290686799.md)
- [Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027](https://longbridge.com/en/news/288717735.md)
- [Cambridge Cognition Publishes 2025 Annual Report and Sets May AGM](https://longbridge.com/en/news/284020943.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**